Vical, Inc.
Vical, Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Vical, Inc..
Vical, Inc. is a company.
Key people at Vical, Inc..
Key people at Vical, Inc..
Vical Incorporated was a biotechnology company that discovered and developed gene-based pharmaceutical product candidates for human therapy, focusing on DNA delivery technologies to treat oncology, infectious diseases, and metabolic disorders.[1][3] It pioneered "naked DNA" technology for vaccines and gene transfer, targeting diseases like cancer, influenza, HIV, herpes, cytomegalovirus, and neurodegenerative conditions through partnerships with major pharma firms such as Merck, Pasteur Merieux Connaught, and Rhone-Poulenc Rorer.[1] The company served patients with genetic and acquired diseases by introducing therapeutic genes into cells, emphasizing ease of manufacturing and cost-effectiveness over traditional methods.[1] Vical was acquired by Brickell Biotech, Inc., in a reverse merger on August 31, 2019, marking the end of its independent operations.[4]
Vical was founded in June 1987 in San Diego, California, as a biotech startup targeting drugs for AIDS, herpes, and other viral diseases.[2] It secured $1 million in seed capital from Biovest Partners, with Biovest principal Timothy Wollaeger serving as chairman, followed by a $2.5 million venture round from investors including Morgenthaler Ventures, Hillman Ventures, Sutter Hill Ventures, Sequoia Capital, and Security Pacific Capital.[2] Wick Goodspeed, with prior executive roles at Baxter International and British Oxygen Healthcare, was hired as president shortly after formation.[2] The company evolved from early viral disease focus to broader gene therapy R&D, signing key collaborations like the 1991 Merck deal for infectious disease vaccines and expanding into oncology and metabolic proteins by the mid-1990s.[1] Vijay B. Samant joined as President and CEO in November 2000, bringing sales and marketing expertise.[5]
Vical rode the early wave of gene therapy and DNA vaccine innovation in the late 1980s and 1990s, when biotech shifted toward genetic approaches for intractable diseases like AIDS, cancer, and infections amid limited traditional drug options.[1][2] Its timing capitalized on emerging DNA tech post-HIV crisis, influencing pharma's adoption of naked DNA platforms—seen in deals with Merck and others that accelerated vaccine R&D.[1] Market forces like rising infectious disease threats and oncology needs favored its model, contributing to the startup ecosystem via VC backing from Sequoia and Sutter Hill, which funneled capital into San Diego's biotech hub.[2] Vical helped pioneer non-viral gene delivery, paving the way for modern mRNA and DNA therapies, though its influence waned post-acquisition amid biotech consolidation.[4]
Vical's legacy as a gene therapy trailblazer endures through its DNA tech influence on vaccines and oncology, but as an independent entity, it ceased with the 2019 reverse merger into Brickell Biotech, shifting focus to dermatology under new leadership.[4] Brickell may leverage Vical's delivery expertise amid rising demand for genetic medicines in immuno-oncology and pandemics. Trends like CRISPR advancements and mRNA dominance could revive similar platforms, potentially evolving Vical's IP through Brickell or licensing—watch for pipeline progress in infectious diseases as global health threats persist. This early biotech pioneer's story underscores how foundational tech seeds enduring ecosystem impact.
